Aspirin

Aspirin, chemically designated acetylsalicylic acid (ASA; systematically named 2-acetoxybenzoic acid, molecular formula C9H8O4, molar mass 180.16 g/mol, weak organic acid with pKa = 3.49), is the prototypical non-steroidal anti-inflammatory drug (NSAID), analgesic, antipyretic, and antiplatelet agent. Synthesized in stable crystalline form on August 10, 1897, by German chemist Felix Hoffmann (working with Arthur Eichengrün and pharmacologist Heinrich Dreser at Friedrich Bayer & Co.) via the acetylation of plant-derived salicylic acid with acetic anhydride, aspirin remains one of the most widely consumed small-molecule pharmaceuticals in human history (>40,000 metric tons or ~50–100 billion tablets consumed annually worldwide). Unlike all other clinical NSAIDs (such as ibuprofen, naproxen, indomethacin, and celecoxib), which inhibit their target enzymes via reversible non-covalent competition, aspirin operates via a suicide-substrate covalent mechanism discovered in 1971 by British pharmacologist Sir John R. Vane (1982 Nobel Prize in Physiology or Medicine) and structurally defined by Philip Majerus and Garret FitzGerald: it irreversibly transfers its acetyl group (-COCH3) onto the hydroxyl group of a single conserved active-site serine residue—Ser530 in Cyclooxygenase-1 (COX-1 / PTGS1) and Ser516 in Cyclooxygenase-2 (COX-2 / PTGS2)—blocking the conversion of arachidonic acid into pro-inflammatory prostaglandins (PGE2, PGI2) and pro-thrombotic thromboxane A₂ (TXA2).

Extracts of white willow bark (Salix alba) and meadowsweet (Filipendula ulmaria, formerly Spiraea ulmaria) rich in natural salicylates were documented for fever and pain in the Egyptian Ebers Papyrus (~1534 BCE), the Hippocratic Corpus (~400 BCE), and Reverend Edward Stone's 1763 report to the Royal Society. In the 19th century, Johann Buchner (1828) and Henri Leroux (1829) isolated the β-glucoside salicin from willow bark; Raffaele Piria (1838) converted salicin into salicylic acid (2-hydroxybenzoic acid); and Hermann Kolbe (1859) invented the industrial Kolbe-Schmitt carboxylation of sodium phenoxide with CO2. Because oral salicylic acid (4–6 g/day) caused gastric irritation and tinnitus (salicylism), Felix Hoffmann—working with Arthur Eichengrün at Bayer in 1897—reacted salicylic acid with acetic anhydride ((CH3CO)2O) to mask the phenolic -OH as an acetate ester (2-acetoxybenzoic acid), marketed in 1899 as Aspirin (A- from acetyl, -spir- from Spiraea).

In 1971, John Vane demonstrated that aspirin blocks prostaglandin biosynthesis, followed in 1975 by Gerald Roth and Philip Majerus, who proved that aspirin covalently acetylates platelet cyclooxygenase (PGHS).

Structural Biochemistry of the Cyclooxygenase Channel and Serine Acetylation

Prostaglandin G/H synthases (PGHS-1 / COX-1 and PGHS-2 / COX-2) are homodimeric, heme-containing ER membrane enzymes with two coupled active sites: a hydrophobic cyclooxygenase (COX) tunnel where a Tyr385 radical oxygenates arachidonic acid (20:4 ω-6) into PGG2, and a peroxidase (POX) site that reduces PGG2 to PGH2 (the precursor of PGE2, PGI2, and TXA2).

Inside the COX tunnel, aspirin's carboxylate (-COO−) salt-bridges with Arg120 and transfers its acetyl group (-COCH3) onto a conserved active-site serine hydroxyl (-CH2OH):

ASA (2-Acetoxybenzoic acid) + COX–Ser-OH → Salicylic acid + COX–Ser-O–COCH3 (Irreversible)

• Inactivation of COX-1 (Ser530 Acetylation): In narrow-tunnel COX-1 (lined by Ile523), acetylating Ser530 sterically blocks arachidonic acid access to Tyr385, abolishing PGH2 and TXA2 synthesis (100% loss).
• Redirection of COX-2 (Ser516 Acetylation → Aspirin-Triggered Lipoxins): Inducible COX-2 (upregulated in immunology cascades) has a wider side-pocket (Val523). Acetylating Ser516 blocks prostaglandin synthesis (100%) but converts COX-2 into a 15R-lipoxygenase that oxygenates arachidonic acid into 15(R)-HETE (and ω-3 fatty acids into 18R-HEPE/17R-HDHA), which leukocyte 5-LOX converts into pro-resolving aspirin-triggered lipoxins (ATLs) and resolvins.

Elucidated by Carlo Patrono and Garret FitzGerald in the 1980s, a daily oral dose of 75–100 mg ("low-dose aspirin") achieves >95% cardioprotective inhibition of platelet thromboxane A₂ (TXA2) while preserving vascular endothelial prostacyclin (PGI2)—even though ASA itself disappears from systemic plasma with a half-life of 15 to 20 minutes:

1. Pre-Systemic Acetylation of Platelets in the Portal Vein: Following oral ingestion, unionized aspirin (pKa = 3.49) is absorbed across the stomach and upper small intestine into the portal venous circulation before reaching the liver. As platelets pass through the portal capillary bed, they encounter portal concentrations (20–50 μM) of intact ASA, which acetylates platelet COX-1 at Ser530.
2. Anucleate Platelets Cannot Resynthesize COX-1: Because circulating human platelets are anucleate cytoplasmic fragments shed by bone marrow megakaryocytes (lacking genomic DNA), an acetylated platelet cannot synthesize new COX-1 protein for its entire 8- to 10-day circulatory lifespan. Cumulative daily dosing (75–100 mg/day) saturates platelet COX-1 acetylation to >95% within 3–5 days; recovering baseline hemostasis after stopping aspirin requires 5–7 days as megakaryocytes release ~10–12% newly formed platelets per day.
3. Hepatic First-Pass Deacetylation and Endothelial Resynthesis: When portal blood passes through the liver (first-pass metabolism), hepatic carboxylesterases (CES1/CES2) and plasma cholinesterases hydrolyze 50–70% of intact ASA into salicylic acid (systemic intact ASA Cmax < 2–5 μM). Furthermore, vascular endothelial cells in the systemic arterial tree—which synthesize vasodilatory, anti-aggregatory prostacyclin (PGI2)—are nucleated cells that transcribe and translate fresh COX-1/COX-2 within hours. Consequently, 75–100 mg/day shifts the vascular TXA2 : PGI2 balance selectively against arterial thrombosis, reducing secondary myocardial infarction and ischemic stroke risk by ~20–25% (whereas taking reversible ibuprofen 30–60 minutes before aspirin blocks ASA access to Ser530 and antagonizes cardioprotection).

Beyond cardiovascular prevention and acute ST-elevation myocardial infarction (STEMI, 162–325 mg), long-term daily aspirin use (≥ 5–10 years) reduces the incidence and metastasis of colorectal cancer (adenocarcinoma, including in Lynch syndrome) by ~30–40% via dual inhibition of platelet COX-1 and colonic epithelial COX-2–PGE2 signaling; inter-individual variability in response is studied in pharmacogenomics.

Major clinical adverse effects include:

• Gastrointestinal Ulceration and Bleeding: Loss of gastroprotective COX-1-derived PGE2/PGI2 combined with topical gastric mucosal "ion trapping" (unionized at pH 1.5 → ionized at intracellular pH 7.4).
• Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad): In asthmatics with nasal polyps, blocking COX-1 removes the PGE2–EP2 brake on 5-lipoxygenase (5-LOX), shunting arachidonic acid into bronchoconstrictor cysteinyl leukotrienes (LTC4, LTD4, LTE4).
• Pediatric Reye's Syndrome: Administering aspirin to children with viral influenza or varicella inhibits hepatocyte mitochondrial β-oxidation (LCHAD), precipitating microvesicular hepatic steatosis and hyperammonemic encephalopathy (aspirin is therefore avoided in febrile children except in Kawasaki disease).
• Salicylate Overdose: Causes a mixed primary respiratory alkalosis (medullary respiratory center stimulation) plus high-anion-gap metabolic acidosis (mitochondrial uncoupling), treated by intravenous NaHCO3 urinary alkalinization.

Finally, in plant biology, endogenous salicylic acid (SA) serves as the phytohormone activating NPR1 to induce Pathogenesis-Related (PR) proteins during Systemic Acquired Resistance (SAR) against pathogens.

How does an 81 mg daily dose of aspirin block blood clots for a full week when aspirin itself has a half-life of 15 minutes in the blood?

When you swallow a low-dose (75–100 mg) aspirin tablet, it is absorbed into the portal vein carrying blood from the gut to the liver. Inside the portal circulation—before liver esterases hydrolyze aspirin into salicylic acid (t1/2 ≈ 15–20 min)—aspirin encounters circulating platelets and irreversibly transfers its acetyl group onto Ser530 of platelet COX-1, shutting off pro-clotting thromboxane A₂ (TXA2) synthesis. Because platelets are anucleate cell fragments lacking a nucleus or DNA, they cannot synthesize replacement COX-1 enzyme and remain inactivated for their 8- to 10-day lifespan, whereas nucleated endothelial cells lining systemic arteries quickly synthesize fresh COX enzyme to maintain anti-clotting prostacyclin (PGI2).

Why should patients taking low-dose aspirin for heart protection not take ibuprofen right before their aspirin dose?

Both ibuprofen and aspirin bind inside the same narrow hydrophobic channel of platelet COX-1 near Arg120, but by different mechanisms: ibuprofen is a reversible competitive inhibitor that sits non-covalently in the tunnel for a few hours and then diffuses out, whereas aspirin is an irreversible covalent modifier that acetylates Ser530. If ibuprofen is taken 30–60 minutes before aspirin, ibuprofen occupies the COX-1 tunnel and blocks aspirin from reaching Ser530. Within 15–20 minutes, liver enzymes destroy the unbound aspirin; a few hours later, ibuprofen diffuses out of COX-1, leaving the platelet unacetylated and capable of forming blood clots.

Why does aspirin trigger asthma attacks in patients with Aspirin-Exacerbated Respiratory Disease (AERD)?

In patients with Samter's triad (AERD: asthma, chronic rhinosinusitis with nasal polyps, and NSAID sensitivity), respiratory mast cells and eosinophils rely on baseline COX-1-generated prostaglandin E₂ (PGE2) signaling through the EP2 receptor (via cAMP) to restrain 5-lipoxygenase (5-LOX) activity. When aspirin or any other COX-1-inhibiting NSAID blocks COX-1, PGE2 levels drop and arachidonic acid substrate is shunted into the unrestrained 5-LOX and leukotriene C₄ synthase (LTC4S) pathway, triggering a surge of cysteinyl leukotrienes (LTC4, LTD4, LTE4) that cause acute bronchoconstriction, mucosal swelling, and rhinorrhea (not an IgE-mediated allergy).

1. Vane, J. R. (1971). "Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs." Nature New Biology, 231(25), 232–235. https://doi.org/10.1038/newbio231232a0
2. Loll, P. J., Picot, D., & Garavito, R. M. (1995). "The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H₂ synthase." Nature Structural Biology, 2(8), 637–643. https://doi.org/10.1038/nsb0895-637
3. Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005). "Low-dose aspirin for the prevention of atherothrombosis." New England Journal of Medicine, 353(22), 2373–2383. https://doi.org/10.1056/NEJMra052717
4. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001). "Cyclooxygenase inhibitors and the antiplatelet effects of aspirin." New England Journal of Medicine, 345(25), 1809–1817. https://doi.org/10.1056/NEJMoa003199